We are excited to announce that Cloudbyz has signed a strategic partnership with Digital China, a prominent leader in IT solutions and services in China. This collaboration marks a major milestone in Cloudbyz’s mission to expand its innovative eClinical solutions into the rapidly growing China market. With this partnership, we are poised to revolutionize clinical research operations in one of the world’s most dynamic healthcare markets, empowering life sciences companies to accelerate the development of therapies and improve patient outcomes.
Entering the China market represents a significant growth opportunity for Cloudbyz. China, with its rapidly advancing healthcare infrastructure and burgeoning biotech sector, is one of the fastest-growing markets for clinical trials. However, many life sciences companies operating in the region face challenges in streamlining clinical trial processes, improving operational efficiency, and maintaining regulatory compliance. That’s where Cloudbyz comes in.
Our partnership with Digital China will allow us to bring our cutting-edge eClinical solutions to Chinese pharmaceutical, biotech, medical device, and contract research organizations (CROs). By leveraging Cloudbyz’s unified eClinical platform, companies will be able to integrate critical clinical trial management functions such as Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), Randomization and Trial Supply Management (RTSM), eTMF, and Safety & Pharmacovigilance solutions.
Digital China’s extensive experience in China’s technology and regulatory landscapes makes them the ideal partner to guide Cloudbyz’s entry into the market. Together, we will provide life sciences companies with the tools they need to modernize their clinical trial operations and ensure that they meet local regulatory requirements while maintaining global standards of excellence.
Digital China brings over two decades of expertise in navigating China’s complex IT infrastructure, regulatory environment, and business practices. This deep local knowledge will be crucial in adapting Cloudbyz’s solutions to meet the specific needs of Chinese customers, from addressing regulatory compliance to adapting to market expectations.
China is home to some of the world’s largest clinical trials, and there is a growing demand for advanced technologies that can streamline trial operations. With Cloudbyz’s unified platform, customers in China will gain the ability to automate and integrate critical clinical trial processes, reducing administrative burden and minimizing the risk of errors. This increased efficiency will enable companies to complete trials faster and bring products to market sooner.
Cloudbyz’s solutions are designed to help companies maintain the highest standards of patient safety and regulatory compliance. Our integrated Safety & Pharmacovigilance solutions, built natively on the Salesforce platform, will allow Chinese companies to better manage adverse event reporting, ensuring that they meet the safety standards required by local regulatory bodies. Additionally, our eTMF and EDC solutions ensure that clinical trial data is collected, stored, and shared in compliance with global standards.
As Cloudbyz solutions are built on the Salesforce platform, they provide unparalleled scalability and flexibility. This partnership will enable life sciences companies in China to leverage a cloud-based system that can be customized to meet the unique needs of their clinical trials, whether they are running small-scale studies or large, multi-center trials.
By partnering with Digital China, Cloudbyz is not just entering the China market—we are setting the stage for long-term growth. This collaboration will help us establish a strong foundation in the region, which will be essential as we expand our footprint and serve the growing demand for advanced eClinical solutions in the years to come.
With the signing of this partnership, Cloudbyz is officially laying the groundwork for its expansion into the China market. Over the next several months, we will work closely with Digital China to localize our solutions for the Chinese market and begin onboarding our first customers in the region.
As part of this partnership, we will also focus on educating the market on the benefits of unified eClinical solutions. We’ll be hosting webinars, engaging with local life sciences communities, and providing demos to showcase how Cloudbyz can help companies streamline their clinical trials, ensure compliance, and improve patient safety.
The strategic partnership between Cloudbyz and Digital China is more than just a business venture—it represents our shared vision of transforming clinical trial operations in China and around the world. By combining Cloudbyz’s industry-leading eClinical platform with Digital China’s deep local expertise, we are confident that we can drive innovation and improve clinical research outcomes in one of the most important healthcare markets globally.
As we embark on this exciting journey, we look forward to working closely with our new partners and customers in China to accelerate the delivery of life-changing therapies and bring the future of clinical trials to life.
Stay tuned for more updates as we continue to expand and innovate in the China market!
About Cloudbyz
Cloudbyz is a leading provider of unified eClinical solutions built natively on the Salesforce platform. Our platform streamlines and automates clinical trial operations, enabling life sciences companies to accelerate time to market, enhance compliance, and improve patient safety. With a global presence and an unwavering commitment to innovation, Cloudbyz is at the forefront of transforming clinical research operations.
About Digital China
Digital China is a leading IT solutions provider based in China, specializing in delivering innovative technology solutions and services to businesses across various industries. With a focus on cloud computing, data management, and enterprise IT infrastructure, Digital China has been a trusted partner for companies seeking to optimize their operations in the Chinese market.